Ya-ching C. Hsieh

21 Shelley Road
Glasgow, SCT G120ZD, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel.

The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel.

Journal: Hematology reports

Published: March 11, 2026

Vγ1 γδ T cells steer airway macrophages toward a profibrotic response in an autochthonous lung cancer mouse model.

Vγ1 γδ T cells steer airway macrophages toward a profibrotic response in an autochthonous lung cancer mouse model.

Journal: Science advances

Published: March 04, 2026

Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ.

Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ.

Journal: Nature cell biology

Published: July 23, 2024

Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.

Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.

Journal: PloS one

Published: December 16, 2022

ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture model.

ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture model.

Journal: Scientific reports

Published: June 27, 2022

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.

Journal: Nature communications

Published: April 29, 2022

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Journal: Cell death discovery

Published: July 07, 2021

MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy.

MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy.

Journal: Cancer letters

Published: March 23, 2021

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Journal: Cell death discovery

Published: February 10, 2021

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.

Journal: Leukemia

Published: October 27, 2020

Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.

Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.

Journal: Cancers

Published: October 08, 2020

MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner.

MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner.

Journal: Oncogene

Published: March 20, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026